Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.
The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
Aldevron will manufacture IDT's patented S. pyogenes HiFi Cas9 mutant for research, clinical, and commercial uses.
The companies will develop a portfolio of indexed adapters specifically designed for multiplex NGS and optimized for use on Illumina systems such as the NovaSeq.
The agreement provides researchers with local customer care, and allows them to order reagents from within the country rather than importing them.
The technology has been a core capability of the firm, which is expanding its suite of products to address the broader needs of genomics researchers.
The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.
IDT has licensed the CRISPR/Cpf1 RNA-guided editing system from the Broad Institute and intends to sell it to pharmaceutical and other commercial labs.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.